The Angiogenic Switch Molecule, Secreted FGF-Binding Protein, an Indicator of Early Stages of Pancreatic and Colorectal Adenocarcinoma

Seminars in Oncology

Volumn 33, Issue SUPPL. 11, 2006, Pages 50-56

  Tassi, Elena ^a   Wellstein, Anton ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; BINDING PROTEIN; CHAPERONE; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR BINDING PROTEIN; PROTEIN P53;

ADENOCARCINOMA; ANGIOGENESIS; ARTICLE; CHROMOSOME 18Q; CHROMOSOME DELETION; COLORECTAL CARCINOMA; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; EARLY CANCER; GENE MUTATION; HISTOCHEMISTRY; HUMAN; IN SITU HYBRIDIZATION; NONHUMAN; ONCOGENE K RAS; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN SECRETION; TUMOR SUPPRESSOR GENE;

EID: 33845439397     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2006.10.014     Document Type: Article

References (98)

1. Greenlee R.T., Hill-Harmon M.B., Murray T., et al. Cancer statistics, 2001. CA Cancer J Clin 51 (2001) 15-36
2. American Cancer Society. Cancer Facts and Figures 2005 (2004), American Cancer Society, Atlanta, GA
3. Vogelstein B., and Kinzler K.W. The Genetic Basis for Human Cancer. Ed 2 (2001), McGraw-Hill, Toronto
4. Kinzler K.W., and Vogelstein B. Lessons from hereditary colorectal cancer. Cell 87 (1996) 159-170
5. Lamlum H., Ilyas M., Rowan A., et al. The type of somatic mutation at APC in familial adenomatous polyposis is determined by the site of the germline mutation: A new facet to Knudson's 'two-hit' hypothesis. Nat Med 5 (1999) 1071-1075
6. Levy D.B., Smith K.J., Beazer-Barclay Y., et al. Inactivation of both APC alleles in human and mouse tumors. Cancer Res 54 (1994) 5953-5958
7. Polakis P. The adenomatous polyposis coli (APC) tumor suppressor. Biochem Biophys Acta 1332 (1997) F127-F147
8. Rubinfeld B., Souza B., Albert I., et al. Association of the APC gene product with beta-catenin. Science 262 (1993) 1731-1734
9. Su L.K., Vogelstein B., and Kinzler K.W. Association of the APC tumor suppressor protein with catenins. Science 262 (1993) 1734-1737
10. Bienz M. APC: the plot thickens. Curr Opin Genet Dev 9 (1999) 595-603
11. Munemitsu S., Albert I., Souza B., et al. Regulation of intracellular beta-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein. Proc Natl Acad Sci U S A 92 (1995) 3046-3050
12. Gumbiner B.M. Carcinogenesis: A balance between beta-catenin and APC. Curr Biol 7 (1997) R443-R446
13. Morin P.J. Beta-catenin signaling and cancer. Bioessays 21 (1999) 1021-1030
14. He T.C., Sparks A.B., Rago C., et al. Identification of c-MYC as a target of the APC pathway. Science 281 (1998) 1509-1512
15. Aoki M., Hecht A., Kruse U., et al. Nuclear endpoint of Wnt signaling: Neoplastic transformation induced by transactivating lymphoid-enhancing factor 1. Proc Natl Acad Sci U S A 96 (1999) 139-144
16. Tetsu O., and McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398 (1999) 422-426
17. Moser A.R., Pitot H.C., and Dove W.F. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 247 (1990) 322-324
18. Campbell S.L., Khosravi-Far R., Rossman K.L., et al. Increasing complexity of Ras signaling. Oncogene 17 (1998) 1395-1413
19. Almoguera C., Shibata D., Forrester K., et al. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53 (1988) 549-554
20. Bos J.L., Fearon E.R., Hamilton S.R., et al. Prevalence of ras gene mutations in human colorectal cancers. Nature 327 (1987) 293-297
21. Forrester K., Almoguera C., Han K., et al. Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. Nature 327 (1987) 298-303
22. Kressner U., Bjorheim J., Westring S., et al. Ki-ras mutations and prognosis in colorectal cancer. Eur J Cancer 34 (1998) 518-521
23. Bos J.L. ras oncogenes in human cancer: A review. Cancer Res 49 (1989) 4682-4689
24. Fearon E.R., and Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 61 (1990) 759-767
25. Shields J.M., Pruitt K., McFall A., et al. Understanding Ras: 'it ain't over 'til it's over'. Trends Cell Biol 10 (2000) 147-154
26. Vogelstein B., Fearon E.R., Hamilton S.R., et al. Genetic alterations during colorectal-tumor development. N Engl J Med 319 (1988) 525-532
27. Shibata D., Reale M.A., Lavin P., et al. The DCC protein and prognosis in colorectal cancer. N Engl J Med 335 (1996) 1727-1732
28. Cho K.R., Oliner J.D., Simons J.W., et al. The DCC gene: structural analysis and mutations in colorectal carcinomas. Genomics 19 (1994) 525-531
29. Chen Y.Q., Hsieh J.T., Yao F., et al. Induction of apoptosis and G2/M cell cycle arrest by DCC. Oncogene 18 (1999) 2747-2754
30. Tarafa G., Villanueva A., Farre L., et al. DCC and SMAD4 alterations in human colorectal and pancreatic tumor dissemination. Oncogene 19 (2000) 546-555
31. Miyaki M., Iijima T., Konishi M., et al. Higher frequency of Smad4 gene mutation in human colorectal cancer with distant metastasis. Oncogene 18 (1999) 3098-3103
32. Koyama M., Ito M., Nagai H., et al. Inactivation of both alleles of the DPC4/SMAD4 gene in advanced colorectal cancers: identification of seven novel somatic mutations in tumors from Japanese patients. Mutat Res 406 (1999) 71-77
33. Salovaara R., Roth S., Loukola A., et al. Frequent loss of SMAD4/DPC4 protein in colorectal cancers. Gut 51 (2002) 56-59
34. Baker S.J., Fearon E.R., Nigro J.M., et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 244 (1989) 217-221
35. Bunz F., Hwang P.M., Torrance C., et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 104 (1999) 263-269
36. Zeng Z.S., Sarkis A.S., Zhang Z.F., et al. p53 nuclear overexpression: an independent predictor of survival in lymph node-positive colorectal cancer patients. J Clin Oncol 12 (1994) 2043-2050
37. Leahy D.T., Salman R., Mulcahy H., et al. Prognostic significance of p53 abnormalities in colorectal carcinoma detected by PCR-SSCP and immunohistochemical analysis. J Pathol 180 (1996) 364-370
38. Allegra C.J., Paik S., Colangelo L.H., et al. Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: A National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J Clin Oncol 21 (2003) 241-250
39. Garrity M.M., Burgart L.J., Mahoney M.R., et al. Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: A North Central Cancer Treatment Group Study. J Clin Oncol 22 (2004) 1572-1582
40. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA Cancer J Clin 56 (2006) 106-130
41. Bodner W.R., Hilaris B.S., and Mastoras D.A. Radiation therapy in pancreatic cancer: Current practice and future trends. J Clin Gastroenterol 30 (2000) 230-233
42. Berlin J.D., and Rothenberg M. Chemotherapy for resectable and advanced pancreatic cancer. Oncology (Williston Park) 15 (2001) 1241-1249
43. Hruban R.H., Adsay N.V., Albores-Saavedra J., et al. Pancreatic intraepithelial neoplasia: A new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol 25 (2001) 579-586
44. Sessa F., Solcia E., Capella C., et al. Intraductal papillary-mucinous tumours represent a distinct group of pancreatic neoplasms: An investigation of tumour cell differentiation and K-ras, p53 and c-erbB-2 abnormalities in 26 patients. Virchows Arch 425 (1994) 357-367
45. Hruban R.H., Wilentz R.E., and Kern S.E. Genetic progression in the pancreatic ducts. Am J Pathol 156 (2000) 1821-1825
46. Hruban R.H., Offerhaus G.J., Kern S.E., et al. Tumor-suppressor genes in pancreatic cancer. J Hepatobiliary Pancreat Surg 5 (1998) 383-391
47. Folkman J., and Shing Y. Angiogenesis. J Biol Chem 267 (1992) 10931-10934
48. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 6 (2000) 389-395
49. Hanahan D., and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 (1996) 353-364
50. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29 suppl 16 (2002) 15-18
51. Risau W. Development and differentiation of endothelium. Kidney Int Suppl 67 (1998) S3-S6
52. Baish J.W., and Jain R.K. Fractals and cancer. Cancer Res 60 (2000) 3683-3688
53. Carmeliet P., and Jain R.K. Angiogenesis in cancer and other diseases. Nature 407 (2000) 249-257
54. Helmlinger G., Yuan F., Dellian M., et al. Interstitial pH and pO2 gradients in solid tumors in vivo: High-resolution measurements reveal a lack of correlation. Nat Med 3 (1997) 177-182
55. Maniotis A.J., Folberg R., Hess A., et al. Vascular channel formation by human melanoma cells in vivo and in vitro: Vasculogenic mimicry. Am J Pathol 155 (1999) 739-752
56. Hashizume H., Baluk P., Morikawa S., et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 156 (2000) 1363-1380
57. Hobbs S.K., Monsky W.L., Yuan F., et al. Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment. Proc Natl Acad Sci U S A 95 (1998) 4607-4612
58. Dvorak H.F., Nagy J.A., Feng D., et al. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr Top Microbiol Immunol 237 (1999) 97-132
59. Benjamin L.E., Golijanin D., Itin A., et al. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 103 (1999) 159-165
60. Folberg R., Hendrix M.J., and Maniotis A.J. Vasculogenic mimicry and tumor angiogenesis. Am J Pathol 156 (2000) 361-381
61. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 285 (1971) 1182-1186
62. Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 175 (1972) 409-416
63. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
64. Folkman J. What is the evidence that tumors are angiogenesis dependent?. J Natl Cancer Inst 82 (1990) 4-6
65. Korc M. Pathways for aberrant angiogenesis in pancreatic cancer. Mol Cancer 2 (2003) 1-8
66. Siddiqi I., Funatomi H., Kobrin M.S., et al. Increased expression of keratinocyte growth factor in human pancreatic cancer. Biochem Biophys Res Commun 215 (1995) 309-315
67. Kuwahara K., Sasaki T., Kuwada Y., et al. Expressions of angiogenic factors in pancreatic ductal carcinoma: A correlative study with clinicopathologic parameters and patient survival. Pancreas 26 (2003) 344-349
68. Yamanaka Y., Friess H., Buchler M., et al. Overexpression of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced tumor stage. Cancer Res 53 (1993) 5289-5296
69. Kornmann M., Ishiwata T., Beger H.G., et al. Fibroblast growth factor-5 stimulates mitogenic signaling and is overexpressed in human pancreatic cancer: evidence for autocrine and paracrine actions. Oncogene 15 (1997) 1417-1424
70. Kleeff J., Kothari N.H., Friess H., et al. Adenovirus-mediated transfer of a truncated fibroblast growth factor (FGF) type I receptor blocks FGF-2 signaling in multiple pancreatic cancer cell lines. Pancreas 28 (2004) 25-30
71. Kornmann M., Ishiwata T., Matsuda K., et al. IIIc isoform of fibroblast growth factor receptor 1 is overexpressed in human pancreatic cancer and enhances tumorigenicity of hamster ductal cells. Gastroenterology 123 (2002) 301-313
72. Kornmann M., Beger H.G., and Korc M. Role of fibroblast growth factors and their receptors in pancreatic cancer and chronic pancreatitis. Pancreas 17 (1998) 169-175
73. Wagner M., Lopez M.E., Cahn M., et al. Suppression of fibroblast growth factor receptor signaling inhibits pancreatic cancer growth in vitro and in vivo. Gastroenterology 114 (1998) 798-807
74. Wray C.J., Rilo H.L., and Ahmad S.A. Colon cancer angiogenesis and antiangiogenic therapy. Expert Opin Investig Drugs 13 (2004) 631-641
75. Mancuso A., and Sternberg C.N. Colorectal cancer and antiangiogenic therapy: What can be expected in clinical practice?. Crit Rev Oncol Hematol 55 (2005) 67-81
76. Dirix L.Y., Vermeulen P.B., Hubens G., et al. Serum basic fibroblast growth factor and vascular endothelial growth factor and tumour growth kinetics in advanced colorectal cancer. Ann Oncol 7 (1996) 843-848
77. Landriscina M., Cassano A., Ratto C., et al. Quantitative analysis of basic fibroblast growth factor and vascular endothelial growth factor in human colorectal cancer. Br J Cancer 78 (1998) 765-770
78. Galzie Z., Fernig D.G., Smith J.A., et al. Invasion of human colorectal carcinoma cells is promoted by endogenous basic fibroblast growth factor. Int J Cancer 71 (1997) 390-395
79. Stoeltzing O., Liu W., Reinmuth N., et al. Angiogenesis and antiangiogenic therapy of colon cancer liver metastasis. Ann Surg Oncol 10 (2003) 722-733
80. Tahara E. Growth factors and oncogenes in gastrointestinal cancers. In: Meyers R.A. (Ed). Encyclopedia of Molecular Cell Biology and Molecular Medicine. Ed 2 (2005), Wiley-VCH Verlag GmbH & Co KgaA, Weinheim 1-31
81. Akbulut H., Altuntas F., Akbulut K.G., et al. Prognostic role of serum vascular endothelial growth factor, basic fibroblast growth factor and nitric oxide in patients with colorectal carcinoma. Cytokine 20 (2002) 184-190
82. Powers C.J., McLeskey S.W., and Wellstein A. Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 7 (2000) 165-197
83. Itoh N., and Ornitz D.M. Evolution of the Fgf and Fgfr gene families. Trends Genet 20 (2004) 563-569
84. Presta M., Dell'Era P., Mitola S., et al. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 16 (2005) 159-178
85. Mohammadi M., Olsen S.K., and Ibrahimi O.A. Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev 16 (2005) 107-137
86. Wu D.Q., Kan M.K., Sato G.H., et al. Characterization and molecular cloning of a putative binding protein for heparin-binding growth factors. J Biol Chem 266 (1991) 16778-16785
87. Czubayko F., Smith R.V., Chung H.C., et al. Tumor growth and angiogenesis induced by a secreted binding protein for fibroblast growth factors. J Biol Chem 269 (1994) 28243-28248
88. Czubayko F., Liaudet-Coopman E.D., Aigner A., et al. A secreted FGF-binding protein can serve as the angiogenic switch in human cancer. Nat Med 3 (1997) 1137-1140
89. Kurtz A., Wang H.L., Darwiche N., et al. Expression of a binding protein for FGF is associated with epithelial development and skin carcinogenesis. Oncogene 14 (1997) 2671-2681
90. Tassi E., Al-Attar A., Aigner A., et al. Enhancement of fibroblast growth factor (FGF) activity by an FGF-binding protein. J Biol Chem 276 (2001) 40247-40253
91. Ray P., Tassi E., Liu X.-H., et al. Role of fibroblast growth factor-binding protein in the pathogenesis of HIV-associated hemolytic uremic syndrome. Am J Physiol 290 (2006) R105-R113
92. Mongiat M., Otto J., Oldershaw R., et al. Fibroblast growth factor-binding protein is a novel partner for perlecan protein core. J Biol Chem 276 (2001) 10263-10271
93. Xie B., Tassi E., Swift M.R., et al. Identification of the fibroblast growth factor (FGF)-interacting domain in a secreted FGF-binding protein by phage display. J Biol Chem 281 (2006) 1137-1144
94. McDonnell K., Bowden E.T., Cabal-Manzano R., et al. Vascular leakage in chick embryos after expression of a secreted binding protein for fibroblast growth factors. Lab Invest 85 (2005) 747-755
95. Kagan B.L., Henke R.T., Cabal-Manzano R., et al. Complex regulation of the fibroblast growth factor-binding protein in MDA- MB-468 breast cancer cells by CCAAT/enhancer-binding protein beta. Cancer Res 63 (2003) 1696-1705
96. Ray R., Cabal-Manzano R., Moser A.R., et al. Up-regulation of fibroblast growth factor-binding protein, by beta-catenin during colon carcinogenesis. Cancer Res 63 (2003) 8085-8089
97. Tassi E., Henke R.T., Bowden E.T., et al. Expression of a fibroblast growth factor-binding protein during the progression of pancreas and colorectal adenocarcinoma. Cancer Res 66 (2006) 1191-1198
98. Herfarth H., Brand K., Rath H.C., et al. Nuclear factor-kappa B activity and intestinal inflammation in dextran sulphate sodium (DSS)-induced colitis in mice is suppressed by gliotoxin. Clin Exp Immunol 120 (2000) 59-65